Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7PVH4
|
|||
| Drug Name |
LPN023
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | IgA nephropathy [ICD-11: MF8Y] | Phase 2 | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor B (CFB) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Alternative complement activation | |||
| Activation of C3 and C5 | ||||
| Regulation of Complement cascade | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03373461) Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation. U.S. National Institutes of Health. | |||
| REF 2 | Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.